Tschabitscher Patricia, Homaier Irmgard, Lichtenschopf Alfred, Groman Ernest
Pfizer Corporation Austria, Wien, Austria.
Wien Med Wochenschr. 2009;159(1-2):17-23. doi: 10.1007/s10354-008-0636-6.
Every year about 1.2 million deaths attributable to smoking occur in Europe. Effective smoking cessation, therefore, is essential. Varenicline is the first medication specifically developed for smoking cessation. The efficacy of varenicline in smoking cessation is due to its role as a partial agonist/antagonist at the alpha4beta2 nicotine receptors. This dual action causes a reduction in cigarette craving as well as withdrawal symptoms; moreover, it decreases the pleasurable and reinforcing effects of smoking. This article discusses the current clinical data regarding efficacy and safety of varenicline and its role in smoking cessation.
在欧洲,每年约有120万人的死亡可归因于吸烟。因此,有效的戒烟至关重要。伐尼克兰是首个专门开发用于戒烟的药物。伐尼克兰在戒烟方面的疗效归因于其作为α4β2尼古丁受体部分激动剂/拮抗剂的作用。这种双重作用可减少对香烟的渴望以及戒断症状;此外,它还能降低吸烟带来的愉悦感和强化作用。本文讨论了关于伐尼克兰疗效和安全性的当前临床数据及其在戒烟中的作用。